Review of the AMADEO Study: Reducing Proteinuria in Patients with Diabetic Nephropathy with Telmisartan Versus Losartan.
Sterling Rock Falls Clinic Ltd., CGH Medical Center, Sterling, IL, 61081, USA. peter.toth@srfc.com.
Original article: Bakris G, Burgess E, Weir M, Davidai G, Koval S; AMADEO Study Investiagtors. Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. Kidney Int. 2008;74(3):364-369. PRACTICE PEARL: A telmisartan-based regimen showed a greater antiproteinuric effect than a losartan-based regimen at similarly achieved BP levels.
PMID: 20203469 [PubMed - in process]
PMID: 20203469 [PubMed - in process]
関連論文
- Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.
- Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy.
- Angiotensin receptor blockers for the reduction of proteinuria in diabetic patients with overt nephropathy: results from the AMADEO study.
- Effects of angiotensin II type 1 receptor blocker on ambulatory blood pressure variability in hypertensive patients with overt diabetic nephropathy.























